Shah Jatin 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 22, 2021
Insider Transaction Report
Form 4
Shah Jatin
EVP, Chief Medical Officer
Transactions
- Sale
Common Stock
2021-02-18$14.83/sh−1,186$17,590→ 51,791 total
Footnotes (2)
- [F1]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
- [F2]The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.